SAB Biotherapeutics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, SAB Biotherapeutics Inc had 20.52M in cash and cash equivalents.

SAB Biotherapeutics Inc reported 21.32M in total liabilities as of the latest reported quarter, including 10.68M in current liabilities and 10.63M in non-current liabilities.

As of the latest reported quarter, SAB Biotherapeutics Inc's total assets were 172.81M, consisting of 101.05M in current assets and 71.76M in non-current assets.

SAB Biotherapeutics Inc reported 151.49M in total shareholders' equity as of the latest reported quarter.